lidocaine has been researched along with Liver Cirrhosis, Alcoholic in 3 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Liver Cirrhosis, Alcoholic: FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam is an antiepileptic drug approved for use as adjunctive therapy in adults with partial-onset seizures." | 2.71 | Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. ( Brockmöller, J; Coupez, R; Lochs, H; Roots, I; Thomsen, T; Wittstock, M, 2005) |
| " Pharmacokinetic parameters were compared with data from a previous study performed in healthy volunteers." | 1.34 | Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment. ( Brennscheidt, U; Brunnmüller, U; Proppe, D; Seiler, KU; Thomann, P, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brockmöller, J | 1 |
| Thomsen, T | 1 |
| Wittstock, M | 1 |
| Coupez, R | 1 |
| Lochs, H | 1 |
| Roots, I | 1 |
| Brennscheidt, U | 1 |
| Brunnmüller, U | 1 |
| Proppe, D | 1 |
| Thomann, P | 1 |
| Seiler, KU | 1 |
| Schinella, M | 1 |
| Guglielmi, A | 1 |
| Veraldi, GF | 1 |
| Boni, M | 1 |
| Frameglia, M | 1 |
| Caputo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
1 trial available for lidocaine and Liver Cirrhosis, Alcoholic
| Article | Year |
|---|---|
Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Topics: Adult; Anticonvulsants; Caffeine; Humans; Kidney Function Tests; Levetiracetam; Lidocaine; Liver Cir | 2005 |
2 other studies available for lidocaine and Liver Cirrhosis, Alcoholic
| Article | Year |
|---|---|
Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment.
Topics: Adult; Aged; Analgesics, Opioid; Area Under Curve; Biotransformation; Chromatography, Gas; Female; H | 2007 |
Evaluation of the liver function of cirrhotic patients based on the formation of monoethylglycine xylidide (MEGX) from lidocaine.
Topics: Adult; Aged; Evaluation Studies as Topic; Female; Fluorescence Polarization Immunoassay; Humans; Lid | 1993 |